Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-102 in Relapsed/Refractory BPDCN
NCT04109482Phase 2Terminated
- Sponsor
- Mustang Bio
- Start
- Feb 2020
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MB-102 CD123 CAR in Blastic plasmacytoid dendritic cell neoplasm (BPDCN), sponsored by Mustang Bio. Started Feb 2020; status: terminated.
02
Drugs
MB-102 CD123 CAR
03
Conditions
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on NCT04109482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04109482.